46 results on '"Bichoupan, Kian"'
Search Results
2. Real-world experience of treating frozen shoulder using active manipulation under local anesthetic: A retrospective study
3. Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis
4. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV
5. A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants
6. Low Adherence of HIV Providers to Practice Guidelines for Hepatocellular Carcinoma Screening in HIV/Hepatitis B Coinfection
7. Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4
8. HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals
9. Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals
10. Interferon-Free Regimens for Hepatitis C: Combine and Conquer
11. Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents
12. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response
13. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
14. Severe Anemia in Patients on Telaprevir-Based Triple Therapy is Independently Associated with Reduced Kidney Function, Lower Baseline Hemoglobin, and Lower Baseline Platelet Count: 1756
15. Side Effects and Adverse Outcomes of Telaprevir-based Triple Therapy in HCV-positive Patients with and without Advanced Fibrosis: Real Life Experience: 1755
16. An Evidence-based Algorithm for Correcting Vitamin D Deficiency in Patients with Advanced Liver Disease Awaiting Transplantation: 607
17. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy
18. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
19. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
20. Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus
21. 357 The Clinical Spectrum of Liver Injury in Cancer Patients
22. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus
23. Hepatitis B in West African-Born Persons Living in New York City: Is Linkage to Care Enough?
24. Hyperbilirubinemia During Chemotherapy for Genitourinary Malignancy
25. Faculty Opinions recommendation of Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population.
26. Faculty Opinions recommendation of All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
27. MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
28. Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new
29. Faculty Opinions recommendation of Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
30. Faculty Opinions recommendation of Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
31. Faculty Opinions recommendation of Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
32. Hepatitis C Direct-acting Antiviral Agents
33. Faculty Opinions recommendation of Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
34. Faculty Opinions recommendation of The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry.
35. Faculty Opinions recommendation of Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
36. Interferon-Free Regimens for Hepatitis C: Combine and Conquer
37. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
38. The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus
39. Faculty Opinions recommendation of Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.
40. Faculty Opinions recommendation of Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
41. Faculty Opinions recommendation of Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.
42. Faculty Opinions recommendation of Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.
43. Sa1061 Similar GI Side Effects With Once-Daily Versus Twice-Daily Dosing Ribavirin in HCV-Positive Patients on Triple Therapy
44. Pegylated-IFNα2afor HIV/hepatitis C virus coinfected patients: out with the old, in with the new
45. The pharmacokinetic evaluation of boceprevirfor treatment of Hepatitis C virus
46. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.